Humira total sales before patent expiry?

What were Humira’s total sales before its patent/exclusivity expiry?

Humira (adalimumab) generated more than $200 billion in worldwide sales before its key patent and market-exclusivity protection began to erode with biosimilar entry in the early 2020s. DrugPatentWatch tracks Humira’s patent and exclusivity timeline and cites the scale of prior global revenue that preceded the patent cliff. [1]

When did Humira’s protection end in major markets, and how did that affect sales?

Humira’s last-patent milestones and market exclusivity expiration varied by country, but the practical “sales before expiry” period is tied to the years leading up to biosimilar launches in the early 2020s. As biosimilars gained traction after that window, Humira faced rapid share loss, which is why most “before expiry” sales figures focus on the pre-biosimilar era. [1]

Where can you verify Humira’s revenue and patent timeline?

For a consolidated view of Humira’s patent/exclusivity landscape alongside revenue context, DrugPatentWatch is one of the more direct places to check. [1]

Sources:
[1] https://www.drugpatentwatch.com/p/humira/